According to Viatris's latest financial reports the company's current revenue (TTM) is $15.42 B. In 2022 the company made a revenue of $16.26 B a decrease over the years 2021 revenue that were of $17.88 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $15.42 B | -5.14% |
2022 | $16.26 B | -9.08% |
2021 | $17.88 B | 49.73% |
2020 | $11.94 B | 3.87% |
2019 | $11.50 B | 0.58% |
2018 | $11.43 B | -3.98% |
2017 | $11.90 B | 7.5% |
2016 | $11.07 B | 17.47% |
2015 | $9.42 B | 22.15% |
2014 | $7.71 B | 11.73% |
2013 | $6.90 B | 1.97% |
2012 | $6.77 B | 10.54% |
2011 | $6.12 B | 12.46% |
2010 | $5.45 B | 7.02% |
2009 | $5.09 B | -0.87% |
2008 | $5.13 B | |
2006 | $1.52 B | 22.05% |
2005 | $1.24 B | -1.67% |
2004 | $1.27 B | -8.94% |
2003 | $1.39 B | 16.43% |
2002 | $1.19 B | 11.96% |
2001 | $1.07 B |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
OPKO Health
OPK | $0.86 B | -94.40% | ๐บ๐ธ USA |
Onconova Therapeutics ONTX | $0.22 M | -100.00% | ๐บ๐ธ USA |